47 results
Page 2 of 3
424B5
jhn4abg9wrh32n4
6 Mar 15
Prospectus supplement for primary offering
12:00am
424B5
z0wybtjq vka5cl0j4ei
4 Mar 15
Prospectus supplement for primary offering
12:00am
8-K
EX-99.3
y6bwr8 2lzzbx3bq
4 Mar 15
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
8-K
EX-99.1
gn37 2f4fm
12 Aug 14
Company announces successful End-of Phase 2 meeting with the FDA and Phase 3 plans for ITI-007 for schizophrenia
12:00am
424B3
inck gc0jch9g9eq6h
6 May 14
Prospectus supplement
12:00am
424B3
ipb12puhn3p
7 Apr 14
Prospectus supplement
12:00am
8-K
EX-99.1
d6tir zaalu
7 Apr 14
Other Events
12:00am
424B3
ilx0ft2 lympfzgx13fb
4 Apr 14
Prospectus supplement
12:00am
424B3
tjx1fht6a9hwdwic wab
4 Mar 14
Prospectus supplement
12:00am
424B1
0t44d8ocfw 6e
31 Jan 14
Prospectus with pricing info
12:00am
8-K
EX-14.1
0wodlyc6hdc07zzu4vie
7 Jan 14
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
12:00am
424B3
q9iwx o0e
19 Dec 13
Prospectus supplement
12:00am
8-K
EX-99.1
43dwyq4c 5u
9 Dec 13
Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia
12:00am
8-K/A
pr3cydtdcyzg0p wsa
31 Oct 13
Entry into a Material Definitive Agreement
12:00am